Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The goal of this multi-centre phase I/II open-label, single-arm study is to determine the
feasibility, optimal dose, and preliminary efficacy of dexmedetomidine to manage agitated
delirium among patients near the end of life followed by a palliative care provider in a
non-monitored setting. Fifty patients will receive dexmedetomidine (0.2 mcg/kg/hour, titrated
up to 0.7 mcg/kg/hour) subcutaneously. Feasibility (recruitment rate, cost), safety (rate of
adverse events), dosing, and preliminary efficacy (agitation, delirium severity) will be
measured.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bruyere Research Institute Ottawa Hospital Research Institute
Collaborators:
Bruyere Research Institute Elisabeth Bruyere Hospital Foothills Medical Centre Kingston Health Sciences Centre Princess Margaret Hospital, Canada Providence Care Hospital Providence Hospital The Ottawa Hospital